Aytu Biopharma (AYTU) Total Non-Current Liabilities (2015 - 2026)

Aytu Biopharma (AYTU) has reported Total Non-Current Liabilities for 12 consecutive years, with $16.6 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 10.88% year-over-year to $16.6 million in Q1 2026; TTM through Mar 2026 was $16.6 million, a 10.88% decrease from a year earlier, with the FY2025 full-year figure at $42.1 million, up 49.72% from the prior year.
• Total Non-Current Liabilities was $16.6 million for Q1 2026 at Aytu Biopharma, down from $42.2 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $102.1 million in Q1 2022 and troughed at $14.4 million in Q1 2024.
• A 5-year average of $50.2 million and a median of $35.8 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities tumbled 85.37% in 2024 and soared 97.24% in 2025, its largest moves.
• Over 5 years, Total Non-Current Liabilities stood at $85.8 million in 2022, then slumped by 60.15% to $34.2 million in 2023, then tumbled by 37.4% to $21.4 million in 2024, then surged by 97.24% to $42.2 million in 2025, then plunged by 60.76% to $16.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $16.6 million (Q1 2026), $42.2 million (Q4 2025), and $35.8 million (Q3 2025), per Business Quant data.